The FDA has granted 510(k) clearance for Accuray, a Sunnyvale, Calif.-based radiation oncology company, to market the Dose Control System (DCS), a feature for Accuray’s TomoTherapy System.
With DCS, the TomoTherapy radiation therapy system becomes the first dose servo-controlled helical delivery system and provides dose stability throughout complex rotational treatments, according to Accuray. Static delivery should also see more consistent dose rates at every gantry angle, the company stated.
DCS automatically adjusts controls that were previously manual processes, meaning small variations in dose rate are corrected by the system with fewer interruptions. The application also stabilizes output over longer duration treatments, such as total marrow and total body irradiation.